IP Library Granted Patent US 9,788,890
Granted Patent B2
US 9,788,890 · App. 13/442,449 · Granted Oct 17, 2017

Methods for evaluating the integrity of a uterine cavity

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,788,890
App. No.
13/442,449
Granted
Oct 17, 2017
Kind
B2
Abstract

Methods, systems and devices for evaluating the integrity of a uterine cavity. A method comprises introducing transcervically a probe into a patient's uterine cavity, providing a flow of a fluid (e.g., CO 2 ) through the probe into the uterine cavity and monitoring the rate of the flow to characterize the uterine cavity as perforated or non-perforated based on a change in the flow rate.

Claims (31)

1. A system for treating a patient's uterus, said system comprising:

a probe having a working end adapted to be positioned in a patient's uterine cavity;

means for introducing a first fluid into the uterine cavity exterior of the working end;

means for introducing a second fluid into the working end;

means for performing a first monitoring test for a first flow rate of the first fluid introduced into the patient's uterine cavity;

means for performing a second monitoring test for a second flow rate of the second fluid introduced into the working end;

means for characterizing a uterine wall as being intact based on a combination of the first and second monitoring tests, wherein the means for characterizing the uterine cavity as being intact comprises means for determining whether the first flow changes during the introduction of the second fluid into the working end; and

means for actuating an ablation mechanism in the working end.

2. The system of claim 1 wherein the actuating means is automatically actuated by a controller.

3. The system of claim 1 wherein the means for performing the first monitoring test and the second monitoring tests performs the first and second monitoring tests contemporaneously.

4. The system of claim 1 wherein the means for performing the first monitoring test and the second monitoring tests performs the first and second monitoring tests sequentially.

5. A system of characterizing a patient's uterus, comprising:

a probe having a working end adapted to be positioned in a patient's uterine cavity;

means for flowing a first fluid into the working end;

means for flowing a second fluid into the uterine cavity exterior of the working end;

means for recording a first pressure in the first fluid during the second fluid flow;

means for recording a second pressure in the first fluid after termination of the second fluid flow;

means for comparing the first and second pressures to thereby characterize the uterine wall as perforated or non-perforated,

wherein the first pressure being greater than the second pressure characterizes the uterine wall as non-perforated, and

wherein the first pressure not being greater than the second pressure characterizes the uterine wall as perforated.

6. The system of claim 5 further comprising means for actuating an ablation mechanism carried by the working end.

7. The system of claim 6 wherein the means for actuating is automatically actuated by a controller.

8. A system for characterizing a patient's uterus, said system comprising:

an expandable structure positionable in a patient's uterine cavity, the expandable structure comprising an expandable thin wall sheath;

means for inflowing a first gas into the uterine cavity exterior of the expandable structure;

means for inflowing a second gas into the expandable thin wall sheath;

means for monitoring a flow rate of the inflow of the first gas with a flow meter; and

means for determining whether the first rate changes during an inflow of the second gas into the expandable thin wall sheath to characterize a uterine wall as being perforated.

9. The system of claim 8 wherein the means for inflowing the second gas into the expandable thin wall sheath is configured to activate at least 2 seconds after the means for inflowing the first gas into the uterine cavity is activated.

10. The system of claim 8 wherein the means for inflowing the second gas into the expandable thin wall sheath is configured to inflow the second gas at a flow rate of 0.8 SLPM.

11. The system of claim 8 wherein the expandable structure comprises a frame in an interior chamber of the expandable thin wall sheath, further including means for applying a negative pressure to the interior chamber to suction the expandable thin wall sheath against the frame.

Assignments (5)
RELEASE OF SECURITY INTEREST Recorded Feb 5, 2026
From: CANADIAN IMPERIAL BANK OF COMMERCE
To: MINERVA SURGICAL, INC.
Reel/Frame 074721/0585 →
SECURITY INTEREST Recorded Jan 30, 2026
From: AXORA MEDICAL, INC.
To: SYMBIOTIC CAPITAL AGENCY LLC, AS ADMINISTRATIVE AGENT AND COLLATERAL AGENT
Reel/Frame 074537/0617 →
RELEASE OF SECURITY INTEREST Recorded Oct 12, 2021
From: ARES CAPITAL CORPORATION, AS ADMINISTRATIVE AGENT
To: MINERVA SURGICAL, INC.
Reel/Frame 057770/0451 →
SECURITY INTEREST Recorded Oct 8, 2021
From: MINERVA SURGICAL, INC.
To: CANADIAN IMPERIAL BANK OF COMMERCE
Reel/Frame 057758/0137 →
SECURITY INTEREST Recorded Dec 31, 2019
From: MINERVA SURGICAL, INC.
To: ARES CAPITAL CORPORATION
Reel/Frame 051395/0275 →